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ABSTRACT—Serum lactate levels are traditionally interpreted as a marker of tissue hypoxia and often used clinically as an
indicator of severity and outcome of sepsis/septic shock. Interestingly, recent studies involving the effects of tumor-derived
lactate suggest that lactate itself may have an immunosuppressive effect in its local environment. This finding adds to the
recent advances in immunometabolism that shed light on the importance of metabolism and metabolic intermediates in the
regulation of innate immune and inflammatory responses in sepsis. In this article, we summarize recent studies, showing
that the activation of immune cells requires aerobic glycolytic metabolism and that lactate produced by aerobic glycolysis
may play an immunosuppressive role in sepsis.
KEYWORDS—Aerobic glycolysis, immunosuppression, lactate, sepsis/septic shock

INTRODUCTION

and most T-cell populations (9), a decrease in the number of
lymphoid progenitors (20), a reduction in bone marrow cell
production (21), and a resultant state of immune tolerance/
paralysis in which many immune cells are reprogrammed via
epigenetic alterations to an unresponsive phenotype (22). In
addition, metabolic reprogramming of immune cells may also
contribute to the development of immune dysfunction during
sepsis (23). Importantly, increasing evidence shows that extracellular lactate may have an important regulatory effect on a
variety of immune cells (24). In addition, excellent review
articles have been published showing that aerobic glycolytic
metabolism is necessary for the activation of immune cells (23,
25–28). In this article, we briefly discuss lactate’s potential
inhibitory role in the systemic immune response to sepsis.

Sepsis is a clinical syndrome characterized by systemic
inflammatory response to infection (1–3). In the early stage
of sepsis, activated innate immune cells initiate a significant
increase in both innate immune and inflammatory responses to
clear invading pathogens from the host. If the initial response is
not properly controlled, it will result in exaggerated innate
immune and inflammatory responses that could damage organs
(2, 4) and increase septic mortality (1). Early clinical efforts are
focused on controlling the inflammatory responsive phase of
sepsis. Unfortunately, over the last 20 years unanimously poor
results have been obtained from clinical trials using antiinflammatory targets (5). Recent data show that the mortality
of sepsis has been significantly reduced due to improvements in
the treatment protocols (6). Furthermore, those who survive
from the acute hyperinflammatory responsive phase remain at
an increased risk for secondary and/or nosocomial infection,
and consequential late-stage mortality (7, 8). However, the
mechanisms are incompletely understood. Hotchkiss, Payen,
and Pickkers as well as others recently hypothesized that an
immunosuppressive phase may exist in sepsis/septic patients
(3, 9–15) and may alternatively be a better candidate for
therapy (16, 17). Although this hypothesis seems controversial
(18, 19), there are number of factors that contribute to immunosuppression, including the apoptosis of innate immune cells

SERUM LACTATE LEVELS IN SEPSIS
The measurement of serum lactate levels is often incorporated in the clinical management of critical illness, particularly
in cases of severe sepsis and septic shock (29). In this context,
serum lactate is typically used to evaluate disease severity,
treatment response, and prognosis (30). The recent sepsis-3
guidelines recommend that persistence of a serum lactate more
than 2 mmol/L, despite adequate fluid resuscitation, should be
included as a new criterion when clinically defining septic
shock (31). This recommendation is based on the recognition
that lactate levels correlate strongly and positively with disease
severity, morbidity, and mortality in the context of sepsis (32,
33). Published literature has shown that high concentrations of
serum lactate could be a predictor of mortality, whereas reduced lactate levels have been reported to be associated with
improved clinical outcomes (15, 29, 34–38). Vincent et al. (39)
recently published an excellent review article regarding the
value of blood lactate kinetics in critically ill patients. The
authors systematically searched the published literatures, collected data from 96 studies, and concluded that a better
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outcome was associated with decreasing blood lactate
concentrations. This was not limited to septic patients, suggesting that the value of lactate kinetics seems to be valid regardless
of the initial value (39). The authors preferred using the term
lactate kinetics that reflect the greater lactate production than
clearance (39). Indeed, recent studies highlight the important
role of immune cells in the production of lactate through
aerobic glycolytic metabolism (25, 26, 40, 41).
INCREASED LACTATE PRODUCTION BY
ACTIVATED IMMUNE CELLS THROUGH AEROBIC
GLYCOLYSIS
Over half a century ago, Dr. Otto Warburg observed that
various cancer cells metabolize glucose directly to lactate
despite the presence of abundant oxygen in the environment
(42). Initially termed the Warburg effect, this phenomenon is
now more commonly referred to as aerobic glycolysis. Recently, the transient utilization of aerobic glycolysis has been
observed in many activated immune cells (43, 44). Although
it is significantly less favorable energetically, there are several
advantages to this type of metabolism with regard to immune
function. First, an adequate immune response requires rapid
energy production, and aerobic glycolysis provides the essential ATP immediately (45). Second, aerobic glycolysis and
parallel increases in the pentose phosphate pathway provide
important precursors for the synthesis of lipids, amino acids,
and nucleotides that are required for rapid cellular growth and
proliferation (25). In addition to supporting the basic energy
requirements of the dividing cell, altered metabolism is now
known to play an important and direct role in regulating
changes in immune cell phenotype. For example, recent
studies have shown that metabolic enzymes and their products
can stimulate the release of alarmins from cells (46), act as
bacterial component receptors (47), promote epigenetic
modification of histones for trained immunity (48), regulate
microRNA expression (49), and participate in various other
immunoregulatory processes. Collectively, these findings
suggest that the transient adoption of aerobic glycolysis in
the immune response may also play an active role in regulating
cell phenotype (50).
Indeed, the switch to aerobic glycolysis seems to play an
important role in the inflammatory response by the innate
immune system. Toll-like receptors (TLRs) are critical in the
induction of innate immune and inflammatory responses. TLRs
could bind with their ligands, including bacterial components
and endogenous ligands, and initiate a cellular signaling cascade that ultimately results in transcriptional regulatory
changes within the cell (51, 52). For example, lipopolysaccharides (LPS) binds with TLR4 on dendritic cells (DCs) and
macrophages, leading to a metabolic transition from oxidative
phosphorylation to aerobic glycolysis and resulting in a proinflammatory phenotype (53, 54, 40). Suzuki et al. recently
outlined the differential reliance of proinflammatory (M1)
macrophages on aerobic glycolysis. This is in contrast to
alternative (M2) phenotypes that rely more heavily on oxidative
phosphorylation (55). In addition to these observations, in vitro
inhibition of glycolysis seems to reprogram innate immune
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cells to a more anti-inflammatory state, further highlighting the
importance of metabolism in cell phenotype (56, 57).
In addition, adaptive immunity also plays an important role
in mediating the pathogen-specific and delayed response in
sepsis. The metabolic regulation of adaptive immune cells has
been reported in subsets of both B and T lymphocytes that adopt
a Warburg-like metabolism upon activation (58–60). In lymphocytes, metabolic regulation seems to be different between Teffector (Teff) cells and T-regulatory (Treg) cells. Michalek et al.
recently reported that Teff cells exhibit greater expression of the
glucose transporter 1 (GLUT1) and elevated levels of glycolysis, while Treg cells primarily rely on fatty acid oxidation (61).
This finding may highlight a characteristic metabolic difference between predominantly proinflammatory cells. For example, Teff and M1 macrophage subtypes rely primarily on
glycolysis, whereas Treg and M2 macrophage subtypes use
fatty acid oxidation. Ultimately, these variations may represent
an important feature by which immune cells can respond
differently to metabolites present in their surroundings.
DECREASED PRODUCTION OF LACTATE
IMPROVES SURVIVAL OUTCOME OF SEPTIC MICE
Critical illness usually causes a metabolic shift from mitochondrial oxidative phosphorylation to aerobic glycolysis. This
transition is associated with lactate production, multiple organ
dysfunction, and poor outcomes. As previously mentioned,
utilization of aerobic glycolytic metabolism by activated immune cells could contribute to increase lactate production.
Nalos et al. used transcriptomic analysis to examine the cellular
metabolism of circulating blood cells from nonhypoxic critically ill patients and observed a significant reprogramming of
metabolic pathways during critical illness. These authors concluded that aerobic glycolysis does exist in nonhypoxic cells
during critical illness (62). The increased lactate production
may also indicate a metabolic shift to an inflammatory glycolysis. Palsson-McDermott et al. have shown that stimulation of
macrophages with LPS significantly increased the expression
of pyruvate kinase M2 (PKM2), a critical modulator of IL-1b
production, macrophage polarization, glycolytic reprogramming, and Warburg metabolism (63). Furthermore, activation
of PKM2 attenuated LPS-induced proinflammatory M1 macrophage phenotype and promoted traits typical of an M2
macrophage (63). Xie et al. (64) from the same group reported
that PKM2-mediated glycolysis promotes inflammasome activation by modulating EIF1AK2 phosphorylation in macrophages. In accordance with these findings, pharmacological
inhibition of the PKM2-EIF2AK2 pathway has been shown to
protect mice from lethal endotoxemia and polymicrobial sepsis
(64). Inhibition of aerobic glycolysis by either 2-deoxy-Dglycose (2-DG) or PKM2 inhibitor also markedly improves
survival outcome in polymicrobial sepsis, and reduces serum
lactate levels and HMGB1 release (46). Wang et al. reported a
similar observation that inhibition of aerobic glycolysis by 2DG significantly improved survival outcome in bacterial sepsis
(65) and reduced LPS-induced inflammation in vivo (66).
Recently, Zheng et al. (67) reported that sepsis-increased
glycolysis also contributes to cardiomyopathy and mortality.
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Inhibition of glycolysis by 2-DG markedly improves cardiac
function and survival outcome by improving mitochondrial
function and inflammatory responses (67). Collectively, the
current published literature indicates that sepsis and endotoxin
could increase aerobic metabolism and produce more lactate
that may ultimately alter the function of immune cells. Understanding the mechanisms by which metabolic switching regulates the processes of immune response could be a novel
research topic in sepsis.
LACTATE MODULATES THE IMMUNE RESPONSE
Previous studies have shown that high levels of lactate could
downregulate the rate-limiting glycolytic enzymes hexokinase
and phosphofructokinase in a variety of tissues (68) and
immune cells (69). Therefore, given the importance of aerobic
glycolysis in activated immune cells, the downregulation of
these rate-limiting glycolytic enzymes may have important
implications on cellular function. Indeed, a growing body of
evidence suggests that tumor-derived lactate has clinically
relevant immunosuppressive effects on a variety of cell types
in the surrounding microenvironment (70). Interestingly, in
cancer research, the immunologic changes of immune cells
are very similar to those observed in the immunosuppressive
phase of sepsis. It would be interesting to investigate the effect
of increased lactate on immune cell function during sepsis.
LACTATE AND INNATE IMMUNE CELL FUNCTION
Recent and ongoing studies have explored the potential
immunomodulatory effects of lactate on innate immune cells,
primarily macrophages and DCs. These cells serve a fundamental role as antigen-presenting cells, and act as gatekeepers
for the activation of lymphocyte B and T cells in the adaptive
response. In the context of sepsis, impaired function of innate
immunity not only limits the response to primary infection, but
also damages important barriers to secondary nosocomial
infection (17). A prominent feature of protracted sepsis is
the inappropriate development of immunologic tolerance toward pathogens (9, 71). For example, DCs transition toward a
progressively tolerogenic phenotype and promote immunosuppressive regulatory T-cell differentiation (72). The mechanisms
underlying this transition may involve a significant metabolic
dysfunction within these cells (23, 73). Indeed, recent studies
have reported that the addition of exogenous lactate to growth
medium containing DCs induced metabolic reprogramming
and ultimately triggered innate immune cells to adapt a more
tolerogenic phenotype (73, 74). These authors proposed that the
unfavorable concentration gradient of lactate may prevent its
diffusion-mediated export from immunogenic DCs that rely on
aerobic glycolysis. It has also been reported that lactate in
peritoneal dialysis solutions may inhibit LPS-induced maturation of DCs (75).
Recently, the effects of lactate on the functioning and
differentiation of macrophages have been reported (56, 76,
77). In the late stage of sepsis, macrophages are often observed
as having a predominantly immunosuppressive M2 phenotype
configuration that may have a critical role in the pathogenesis
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of immune system dysfunction (56, 77). Interestingly, the M2
phenotype has also been observed in the local environments of
tumor cells, where it may contribute to immune system evasion
(76). Colegio et al. (76) reported that lactate may serve as the
primary mediator responsible for promoting the M2 inhibitory
polarization of macrophages. In subsequent in vitro experiments involving bone marrow-derived macrophages, these
authors reported that lactate was consistently capable of inducing an M2-like macrophage polarization by an HIF-1a-dependent mechanism. In addition, lactate treatment also increased
production of M2-associated genes (VEGF and Arg1) and
markers (Fizz1, Mgl1, and Mgl2) in a dosage-dependent manner (76). Selleri et al. (78) have similarly reported that lactate
induces a preferential differentiation of monocytes into M2
macrophages in a dose-dependent fashion by metabolic reprogramming. Furthermore, it has been reported that lactate
decreases TNF-a secretion by human monocytes (79), potentially by reducing NF-kB activation and delaying LPS-induced
signal transduction (80).
To explore the mechanisms by which lactate can induce the
macrophage transition to an anti-inflammatory phenotype,
Hoque et al. (81) recently proposed a novel cellular signaling
pathway. This pathway involves the GPR81 receptor that
recognizes lactate and has the ability to induce the transition
of macrophages to the M2 phenotype. As presented in Figure 1,
these authors showed that macrophages treated with LPS in the
presence of lactate exhibited a significant reduction in proinflammatory cytokine production such as Pro-IL1 b, Pro-IL18,
Casp1, and Nlrp3, whereas production of anti-inflammatory
cytokines like IL-10 was not affected. The mechanisms by
which lactate significantly affects LPS-induced production of
proinflammatory cytokines involve the GPR81-dependent antagonism of the TLR4/TLR9-mediated signaling pathway, and
consequently attenuation of LPS-induced NF-kB activation. It
has been reported that GPR81 has an impressively high affinity
for lactate with an estimated EC50 of 4.3 mM/L (82), suggesting that relatively low concentrations of lactate may have
an effect on TLR-mediated NF-kB activation pathway (81).
Lactate has also been reported to influence the bone marrow
stem cell maturation process. Husain et al. have recently shown
that the addition of lactate to the growth medium before
induction of bone marrow stem cell differentiation results in
a significantly increased production of myeloid-derived suppressor cells (MDSCs) when compared with the control (83).
MDSCs are a heterogenous group of cells that have predominantly immunosuppressive effects and play an important role in
cancer development and chronic infectious diseases (84). In
addition, increased MDSCs in sepsis were recently implicated
in the pathogenesis of protracted immune dysfunction (20, 85).
However, to date few studies have neither examined the
metabolic properties of these cells nor fully described the
mechanisms surrounding their origin.
LACTATE AND ADAPTIVE IMMUNE CELL
FUNCTION
In addition to influencing the function of the innate immune
cells, lactate has also been reported to have effects on T-cell
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Possible mechanisms by which lactate can induce the macrophage transition to an anti-inflammatory phenotype.

functioning (86). Haas et al. (69) recently reported that lactate
accumulation in the synovia of rheumatoid arthritis patients
may play a role in the localization of T cells to the site of
inflammation. In vitro studies by this group demonstrated that
sodium lactate inhibited CD4þ cell motility, whereas an acidic
lactate was required to inhibit the motility of CD8þ T cells. In
CD4þ T cells, the effect of lactate (at physiologic pH) seemed
to be dependent on the interruption of glycolysis and required
expression of the Naþ/lactate cotransporter, Slc5a12 (69). In

FIG. 2.

LACTATE

contrast, the inhibitory effect of lactate on CD8þ T cells
required expression of the Slc16a1 proton-coupled lactate
transporter in addition to an acidic microenvironment (69).
These effects were dose-dependent and estimated the EC50 of
lactate to be 10 mM/L (69). However, this concentration is not
significantly greater than what is observed in severe sepsis.
Finally, the authors reported that buffered sodium lactate
induced CD4þ T helper cells toward a TH17 subset, whereas
unbuffered lactic acid inhibited the cytolytic function of CD8þ

Potential role of increased lactate in the regulation of immune cell function.
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T cells (69). At present, there is no study to investigate the
effects of lactate on Treg cells. It is possible that the proposed
Treg cells are less dependent on aerobic glycolysis and primarily
use oxidative phosphorylation for their energy production (61).
Thus, theoretically they may not be susceptible to this type of
metabolic regulation.
CONCLUSION
We have highlighted some of the current research surrounding the potential role of lactate as an immunosuppressive
metabolite (see Fig. 2). Although there are clearly a number
of contributing factors to the development of immune suppression in sepsis, the recent developments in other fields of
research suggest that lactate could be a potential and critical
contributory factor in the regulation of immune function
in sepsis.
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